Pfizer director granted phantom stock units

SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. director James C. Smith received a grant of 7,686.539 Phantom Stock Units as deferred compensation. Each unit represents one phantom share of Pfizer common stock and was valued at $26.67 per unit for this award. After this grant, Smith holds 178,111.302 Phantom Stock Units directly. The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and represent deferred director compensation. According to the terms, these units will be settled in cash or Pfizer common stock, at Smith’s election, after he retires from the Board of Directors.

Insider Trade Summary

Grant/Award: 7,686.539 shares

Grant/Award 1 txn

Insider SMITH JAMES C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units	7,686.539	$26.67	$205K

Holdings After Transaction: Phantom Stock Units — 178,111.302 contracts (Direct)

Footnotes (3)

1. F1. Each unit represents one phantom share of common stock.
2. F2. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
3. F3. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

Key Figures

Phantom units granted: 7,686.539 units Reference price per unit: $26.67 per unit Total phantom units after grant: 178,111.302 units +1 more

4 metrics

Phantom units granted 7,686.539 units Phantom Stock Units grant on 2026-04-23

Reference price per unit $26.67 per unit Valuation used for Phantom Stock Units grant

Total phantom units after grant 178,111.302 units Direct Phantom Stock Units held following transaction

Conversion/exercise price $0.00 Phantom Stock Units exercise price

Key Terms

Phantom Stock Units, Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, deferred director's compensation

3 terms

Phantom Stock Units financial

"Each unit represents one phantom share of common stock."

Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.

Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors financial

"Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors."

deferred director's compensation financial

"These units represent deferred director's compensation that are settled in cash or common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pfizer (PFE) director James C. Smith report in this Form 4 filing?

James C. Smith reported receiving 7,686.539 Phantom Stock Units as a compensation grant. These units track Pfizer’s common stock value and are part of his deferred director compensation, to be settled after he retires from the Board of Directors.

How many Pfizer Phantom Stock Units does James C. Smith hold after this transaction?

After the grant, James C. Smith directly holds 178,111.302 Pfizer Phantom Stock Units. This total reflects his accumulated deferred director compensation under the company’s plan, which will eventually be settled in cash or common stock at his election upon retirement.

What are Pfizer (PFE) Phantom Stock Units as disclosed in this filing?

Each Pfizer Phantom Stock Unit represents one phantom share of common stock. They are bookkeeping units used for deferred compensation, providing economic exposure to Pfizer’s stock performance without immediate share issuance until settlement in cash or stock at a later date.

Under what plan were James C. Smith’s Pfizer Phantom Stock Units granted?

The Phantom Stock Units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This plan allows directors to receive compensation in deferred units tied to Pfizer’s common stock rather than immediate cash payments.

When will James C. Smith’s Pfizer Phantom Stock Units be settled?

The Phantom Stock Units will be settled after James C. Smith retires from Pfizer’s Board of Directors. At that time, these units will be paid out either in cash or in Pfizer common stock, based on his election under the plan’s terms.

What valuation was used for the Pfizer Phantom Stock Units granted to James C. Smith?

The 7,686.539 Phantom Stock Units granted to James C. Smith were valued at $26.67 per unit. This figure reflects the reference price per phantom share used to determine the size of the deferred compensation award disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 06:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH JAMES C

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NEW YORK 10001-2192

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units	(1)	04/23/2026		A		7,686.539(2)		(3)	(3)	Common Stock	7,686.539	$26.67	178,111.302	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.

3. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

	/s/ Shanice A. Reid, by power of atty., for James C. Smith	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)